Posted by Michael Wonder on 10 Apr 2026
Sanofi becomes market authorisation holder for Nuvaxovid in Canada, expanding COVID-19 vaccine choices for Canadians
9 April 2026 - Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 season.
Sanofi today announces it has become the market authorisation holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine.
